BRPI0920240B8 - composição adjuvante - Google Patents

composição adjuvante

Info

Publication number
BRPI0920240B8
BRPI0920240B8 BRPI0920240A BRPI0920240A BRPI0920240B8 BR PI0920240 B8 BRPI0920240 B8 BR PI0920240B8 BR PI0920240 A BRPI0920240 A BR PI0920240A BR PI0920240 A BRPI0920240 A BR PI0920240A BR PI0920240 B8 BRPI0920240 B8 BR PI0920240B8
Authority
BR
Brazil
Prior art keywords
methods
immune response
adjuvant composition
compositions
infections
Prior art date
Application number
BRPI0920240A
Other languages
English (en)
Inventor
Potter Andrew
Mutwiri George
Kindrachuk Jason
Kovacs-Nolan Jennifer
Babiuk Lorne
Elliott Melissa
Kweon Mi-Na
Hancock Robert
Halperin Scott
Lee Song
Van Drunen Littel-Van Den Hurk Sylvia
Gerdts Volker
Original Assignee
Univ Dalhousie
Int Vaccine Institute
Univ British Columbia
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dalhousie, Int Vaccine Institute, Univ British Columbia, Univ Saskatchewan filed Critical Univ Dalhousie
Publication of BRPI0920240A2 publication Critical patent/BRPI0920240A2/pt
Publication of BRPI0920240B1 publication Critical patent/BRPI0920240B1/pt
Publication of BRPI0920240B8 publication Critical patent/BRPI0920240B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

formulação de adjuvante de combinação a presente invenção se refere a métodos e composições para aumentar uma resposta imune para um antígeno selecionado. os métodos são para o tratamento e prevenção de infecções microbiológicas, tais como infecções causadas por bactérias, vírus, fungos e parasitas. os métodos e composições incluem peptídeos de defesa do hospedeiro, polifosfazenos e seqüências imunioestimulatórias para aumentar a resposta imune de um antígeno co-administrado.
BRPI0920240A 2008-10-16 2009-10-15 composição adjuvante BRPI0920240B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19622608P 2008-10-16 2008-10-16
US61/196.226 2008-10-16
PCT/CA2009/001463 WO2010043039A1 (en) 2008-10-16 2009-10-15 Combination adjuvant formulation

Publications (3)

Publication Number Publication Date
BRPI0920240A2 BRPI0920240A2 (pt) 2016-08-02
BRPI0920240B1 BRPI0920240B1 (pt) 2021-01-19
BRPI0920240B8 true BRPI0920240B8 (pt) 2021-05-25

Family

ID=42106164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920240A BRPI0920240B8 (pt) 2008-10-16 2009-10-15 composição adjuvante

Country Status (9)

Country Link
US (2) US9061001B2 (pt)
EP (1) EP2344522B1 (pt)
AU (1) AU2009304552B2 (pt)
BR (1) BRPI0920240B8 (pt)
CA (1) CA2737352C (pt)
DK (1) DK2344522T3 (pt)
HU (1) HUE028497T2 (pt)
NZ (2) NZ591925A (pt)
WO (1) WO2010043039A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043039A1 (en) * 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation
US8999349B2 (en) * 2010-07-27 2015-04-07 The Regents Of The University Of California HMGB1-derived peptides enhance immune response to antigens
WO2013034982A2 (en) * 2011-09-09 2013-03-14 The University Of British Columbia Immunomodulatory peptides for treatment of progressive neurodegenerative diseases
WO2014008406A2 (en) 2012-07-05 2014-01-09 Children's Medical Center Corporation The bacterial biofilm matrix as a platform for protein delivery
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
KR102290205B1 (ko) 2014-06-04 2021-08-20 엑시큐어, 인크. 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR101746635B1 (ko) 2014-12-08 2017-06-13 재단법인 아산사회복지재단 박테로이데스 에시디페시언스를 유효성분으로 포함하는, 대사성 질환 예방 또는 치료용 약학적 조성물
US20190030153A1 (en) * 2015-07-22 2019-01-31 University Of Saskatchewan Mycoplasma vaccines and uses thereof
US11472927B2 (en) 2015-11-18 2022-10-18 University Of Maryland, College Park Polyphosphazenes, methods of making, and uses thereof
TW201731525A (zh) * 2015-11-25 2017-09-16 薩斯喀徹溫大學 治療、預防及診斷豬流行性下痢病毒感染之方法
WO2017172929A1 (en) * 2016-03-29 2017-10-05 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
US10624947B2 (en) 2016-03-29 2020-04-21 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
WO2018009672A1 (en) 2016-07-06 2018-01-11 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11793858B2 (en) 2018-04-13 2023-10-24 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
PE20211960A1 (es) * 2019-02-28 2021-10-04 Univ Saskatchewan Composiciones de lawsonia intracellularis y metodos de uso de las mismas
CA3226187A1 (en) 2021-07-16 2023-01-19 The Board Of Trustees Of The University Of Illinois Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985354A (en) 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5053451A (en) 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5855895A (en) * 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) * 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5891444A (en) * 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US5807757A (en) 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
EP1039935A4 (en) * 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US5760271A (en) * 1997-08-18 1998-06-02 Virus Research Institute, Inc. Production of polyorganophosphazenes
US6207171B1 (en) 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
EP1140164B1 (en) * 1998-12-17 2009-02-11 Sanofi Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
WO2001015727A2 (en) 1999-09-02 2001-03-08 Antigenics Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
EP1297110B1 (en) * 2000-06-23 2009-07-22 Intervet International BV Attenuated bovine respiratory syncytial virus
EP1446162B1 (en) 2001-08-17 2008-10-15 Coley Pharmaceutical GmbH Combination motif immune stimulatory oligonucleotides with improved activity
EP1434602B1 (en) * 2001-10-06 2014-12-17 Merial Limited CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
US20040161470A1 (en) * 2002-11-22 2004-08-19 Alexander Andrianov Preparation of polyphosphazene microspheres
EP1697511A4 (en) * 2003-12-11 2007-11-21 Vaxdesign Corp IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME
US20060008466A1 (en) * 2004-07-07 2006-01-12 University Of Saskatchewan Methods for treating and preventing microbial infections
WO2006050611A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
ES2497441T3 (es) * 2006-08-21 2014-09-22 The University Of British Columbia Péptidos inmunomoduladores catiónicos pequeños
WO2009000089A1 (en) * 2007-06-28 2008-12-31 University Of Saskatchewan Immunomodulatory compositions and methods for treating disease with modified host defense peptides
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
WO2010043039A1 (en) * 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation

Also Published As

Publication number Publication date
AU2009304552A2 (en) 2011-07-07
BRPI0920240B1 (pt) 2021-01-19
US9061001B2 (en) 2015-06-23
NZ591925A (en) 2012-09-28
HUE028497T2 (en) 2016-12-28
NZ601345A (en) 2014-05-30
EP2344522A1 (en) 2011-07-20
CA2737352C (en) 2017-06-27
EP2344522A4 (en) 2013-09-04
BRPI0920240A2 (pt) 2016-08-02
AU2009304552B2 (en) 2015-02-19
US20100239611A1 (en) 2010-09-23
US9408908B2 (en) 2016-08-09
DK2344522T3 (en) 2016-04-18
WO2010043039A1 (en) 2010-04-22
CA2737352A1 (en) 2010-04-22
EP2344522B1 (en) 2016-01-27
AU2009304552A1 (en) 2010-04-22
US20140248313A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
BRPI0920240B8 (pt) composição adjuvante
EP4233898A3 (en) Influenza mrna vaccines
BR112013026929A2 (pt) composição e método para intensificação de uma resposta imune
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
BR112013002729A2 (pt) inibidores de vírus de hepatite c
UY33897A (es) Inhibidores del virus de la hepatitis c
UY32457A (es) Vacuna del virus del dengue inactivado
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
EP4241851A3 (en) Immunogenic compositions
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
GEP20197052B (en) Hyr1-derived compositions and methods of treatment using same
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/196.226 DE 16/10/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL.

B12F Appeal: other appeals
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF